Axxam S.p.A., a premier provider of integrated early discovery services, has announced a strategic partnership with Molecular Health GmbH, a leader in AI-powered drug development solutions. This collaboration aims to revolutionize the identification and validation of therapeutic targets across multiple disease areas.
Integration of Dataome and DiscoveryMAXX
At the heart of the collaboration lies the integration of Molecular Health’s digital drug development platform, Dataome, into Axxam’s DiscoveryMAXX platform. This union merges computational clinical-molecular insight with Axxam’s rigorous biological validation process.
Together, the platforms will deliver data-driven, clinically informed solutions that connect disease insights directly to drug targets and leads. These synergies are expected to enhance precision and speed in early-stage drug discovery for pharma and biotech clients.
Powering Insights Through Structured Data
Dataome is a proprietary platform that curates, integrates, and structures vast volumes of molecular, phenotypic, and clinical data. It draws from public, private, and proprietary datasets to produce causal insights.
These insights empower pharmaceutical companies to improve pipeline decisions, predict drug safety risks, optimize clinical trial strategies, and make more confident investments based on data rather than assumptions.
Leveraging Advanced AI for Target Prediction
Molecular Health applies state-of-the-art artificial intelligence to uncover actionable patterns and causal relationships within complex datasets.
The platform aids in identifying novel, high-potential drug targets that can feed directly into Axxam’s discovery process for further biological assessment.
Bridging In Silico Prediction with Experimental Evidence
Axxam’s DiscoveryMAXX process includes decades of scientific expertise in biology, phenotypic and target-based screening, assay development, and compound profiling.
Through this partnership, computational predictions from Dataome will undergo rigorous biological validation using cutting-edge technologies.
These include in-vitro techniques and models based on induced pluripotent stem cells (iPSCs), which help establish biological relevance and translational applicability of candidate targets early in the discovery process.
Axxam on Translating Predictions into Therapies
Ciriaco Maraschiello, CEO of Axxam, commented:
“Identifying the right target is one of the most critical and challenging steps in drug discovery. At Axxam, we believe that biology-driven validation is key to translating digital assessments and predictions into real-world therapies.
This strategic partnership between a biology powerhouse like Axxam and a precision medicine-focused AI company like Molecular Health is enabling a new level of accuracy and efficiency in the early drug discovery process, allowing our clients to make more informed decisions, faster, in both preclinical and clinical development.”
Molecular Health on the Role of AI in Drug Development
Friedrich von Bohlen, CEO of Molecular Health, added:
“Understanding molecular causalities and variants in phenotypes, diseases and endotypes is essential for pharma and biotech companies to improve efficiency and success rates in drug development.
The integration of our data/AI-based knowledge, simulations and predictions with Axxam’s preclinical biology and chemistry assays and expertise will offer improved and accelerated outcomes in early drug discovery. This will enable our joint clients to gain deeper insights, enhance decision-making, and expand their options for drug discovery and clinical development programmes.”
By combining AI-powered predictions with deep biological insight, Axxam and Molecular Health are creating a new framework for drug discovery that is both scientifically rigorous and operationally agile.
This partnership not only accelerates the pace at which validated therapeutic targets can be identified but also improves the quality and translatability of those targets into viable drug candidates—an increasingly critical factor in today’s complex and cost-intensive development landscape.
Axxam is a leading discovery research organization supporting the life sciences industry with integrated services across the drug discovery value chain.
The company partners with pharmaceutical and biotech companies, start-ups, patient foundations, and academic institutions, offering solutions from hit identification to lead generation across all therapeutic areas and target classes.
Molecular Health is a pioneer in data-driven drug development, offering software-based solutions that combine human expertise, curated biomedical knowledge, and advanced analytics.
With more than a decade of experience, the company applies artificial intelligence to transform complex medical data into actionable insights for pharma and biotech organizations worldwide.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!